Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2007-004814-15-IT
EUCTR2007-004814-15-IT
Active, not recruiting
Not Applicable

Radiochemotherapy in association with capecitabine and oxaliplatin in the treatment of pancreatic and biliary tract, unresectable cancer: a dose escalation study - XelOx -P07

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 sitesOctober 24, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionspancreatic and biliary tract, unresectable cancerMedDRA version: 9.1Level: LLTClassification code 10033611Term: Pancreatic carcinoma non-resectable
DrugsXELODAELOXATIN

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
pancreatic and biliary tract, unresectable cancer
Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Status
Active, not recruiting
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 24, 2007
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Eligibility Criteria

Inclusion Criteria

  • •Histologically proved carcinoma of pancreas or biliary tract
  • •measurable disease
  • •age \>18 years
  • •performance status (ECOG) 0\-1
  • •no previous chemio or radiotherapeutic treatments
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •previous radiotherapy or chemiotherapy
  • •renal failure
  • •hepatic failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist Anakinra for rectal cancer patients. A phase I trial of the German Rectal Cancer Study GroupC20Malignant neoplasm of rectum
DRKS00025477niversitätsklinikum Frankfurt Goethe-Universität Frankfurt am Main12
Active, not recruiting
Not Applicable
eoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial.Advanced K-ras mutated rectal cancer.
EUCTR2008-006312-38-HUSAKK (Swiss Group for Clinical Cancer Research)47
Active, not recruiting
Not Applicable
eoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial.
EUCTR2008-006012-38-HUSAKK (Swiss Group for Clinical Cancer Research)67
Active, not recruiting
Phase 1
Combination of radiotherapy and chemotherapy for patients with oligometastatic colorectal cancer.
EUCTR2011-005296-16-DEniversity Medical Center Hamburg-Eppendorf72
Active, not recruiting
Not Applicable
Preoperative Radiotherapy with Capecitabine and Bevacizumab in locally advanced rectal cancer: CRAB Phase II study - CRAB
EUCTR2008-002902-20-SIOnkološki inštitut Ljubljana